Supporting Health Including Endocrine Treatment for Long Duration

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT07482384
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 49 Years
Healthy Volunteers
Not accepted

Interventions

  • SHIELD portal — BEHAVIORAL
    All participants will receive access to the SHIELD portal. The portal includes educational modules, symptom and side effect tracking, tailored informational resources, and health behavior tools. Participants can access the portal via smartphone, tablet, or computer. The portal is HIPAA compliant and HITRUST certified.

Study Details

This research is being done to pilot an intervention which aims to test a new web- and mobile application ("app")-based supportive care tool (SHIELD portal) and to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease long-term endocrine treatment.

Key Dates

First listed
Mar 19, 2026
Start date
Aug 4, 2026
Status verified
Aug 2026
Primary completion
Jan 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: SHIELD Portal Interventional
    320 participants will be enrolled and will complete the following: Baseline visit (assessments) either by in-person clinic visit or virtually Follow-Up/Post Baseline (3-month assessments) Medical record review (if necessary)

Primary Outcome Measure

Enrollment Yield [ Time Frame: up to 3 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Dana-Farber Cancer InstituteBostonMassachusetts02215
Ann H Partridge, MD, MPH
[email protected]
617-632-6800
Kate Dibble, Ph.D.
[email protected]
617-582-8294

Find similar trials in Boston, MA

Nationwide
Breast cancer trialsOncology trialsBreast oncology trialsWomen's health trials
By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Dana-Farber Cancer Institute· Boston, MA

Related Studies